Sandra Casimiro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5706260/publications.pdf

Version: 2024-02-01

28 papers

853 citations

15 h-index 23 g-index

28 all docs 28 docs citations

28 times ranked

1502 citing authors

#	Article	IF	Citations
1	A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases. Cancers, 2022, 14, 893.	1.7	2
2	Lupin Protein Concentrate as a Novel Functional Food Additive That Can Reduce Colitis-Induced Inflammation and Oxidative Stress. Nutrients, 2022, 14, 2102.	1.7	4
3	The Roadmap of RANKL/RANK Pathway in Cancer. Cells, 2021, 10, 1978.	1.8	29
4	Dynamic modeling of bone remodeling, osteolytic metastasis and PK/PD therapy: introducing variable order derivatives as a simplification technique. Journal of Mathematical Biology, 2021, 83, 39.	0.8	1
5	c-Met expression in renal cell carcinoma with bone metastases. Journal of Bone Oncology, 2020, 25, 100315.	1.0	10
6	Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases. Cancers, 2020, 12, 2034.	1.7	5
7	Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis. Cancer and Metastasis Reviews, 2020, 39, 603-623.	2.7	50
8	Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2-breast cancer. Oncotarget, 2020, 11, 1714-1728.	0.8	15
9	Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancerâ€induced bone loss. British Journal of Clinical Pharmacology, 2019, 85, 1114-1124.	1.1	21
10	Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases. International Journal of Molecular Sciences, 2019, 20, 695.	1.8	18
11	Bone metastasis risk factors in breast cancer. Ecancermedicalscience, 2017, 11, 715.	0.6	79
12	Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?. International Journal of Molecular Sciences, 2016, 17, 1415.	1.8	35
13	N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases. Oncologist, 2016, 21, 1418-1426.	1.9	17
14	Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer. Clinical Colorectal Cancer, 2016, 15, 170-178.e3.	1.0	70
15	Targeting bone metastases in prostate cancer: improving clinical outcome. Nature Reviews Urology, 2015, 12, 340-356.	1.9	87
16	Bone remodeling markers and bone metastases: From cancer research to clinical implications. BoneKEy Reports, 2015, 4, 668.	2.7	45
17	Biological assessment of novel bisphosphonate-containing 99mTc/Re-organometallic complexes. Journal of Organometallic Chemistry, 2014, 760, 197-204.	0.8	14
18	MTA1 Promotes STAT3 Transcription and Pulmonary Metastasis in Breast Cancer. Cancer Research, 2013, 73, 3761-3770.	0.4	61

#	Article	IF	CITATION
19	RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro. PLoS ONE, 2013, 8, e63153.	1.1	66
20	N-telopeptide of type I collagen (NTX) dynamics over one year of determinations in patients with breast cancer (BC) with bone metastases (BM): Predictive factors of outcome Journal of Clinical Oncology, 2013, 31, 9634-9634.	0.8	0
21	Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. OncoTargets and Therapy, 2012, 5, 409.	1.0	14
22	Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clinical and Experimental Metastasis, 2012, 29, 155-164.	1.7	41
23	Zoledronic Acid: Its Use in the Treatment of Breast Cancer. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2353.	0.4	O
24	^{99m} Tc-Tricarbonyl Complexes Functionalized with Anthracenyl Fragments: Synthesis, Characterization, and Evaluation of Their Radiotoxic Effects in Murine Melanoma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 551-563.	0.7	24
25	The critical role of the bone microenvironment in cancer metastases. Molecular and Cellular Endocrinology, 2009, 310, 71-81.	1.6	128
26	Identification of pathogenesis-related ESTs in the crucifer downy mildew oomycete Hyaloperonospora parasitica by high-throughput differential display analysis of distinct phenotypic interactions with Brassica oleracea. Journal of Microbiological Methods, 2006, 66, 466-478.	0.7	8
27	The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. Oncotarget, 0, 7, 41380-41389.	0.8	7
28	Exploring new pathways in endocrine-resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 337-361.	0.5	2